Advertisement

Kaposi’s Sarcoma: A Reevaluation

  • C. E. Orfanos
  • R. Husak
  • U. Wölfer
  • C. Garbe
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 139)

Abstract

Kaposi’s sarcoma (KS) is a multicentric neoplasia of microvascular origin arising during development of immunodeficiency in human immunodeficiency virus (HIV)-infected individuals. More than 130 patients with HIV-associated KS (98% male homosexuals; median age, 35 years) have been diagnosed at the Department of Dermatology, University Medical Center Steglitz, Berlin, during the years 1982–1992. Mucocutaneous and visceral involvement was a common finding in patients with HIV-associated KS, increasing from 39% at the first visit to 65% at the last observation. In 90% of the patients significant immunosuppression was found (75% had a CD4+ count < 200/mm3) at the time of first diagnosis. However, immunosuppression was not a prerequisite for the development of KS, since the tumor had been diagnosed before severe immunosuppression was present in about 10% of the patients. Significant prognostic predictors for the final outcome were: (a) the degree of immunosuppression, (b) the presence of mucosal and visceral manifestation, and (c) the past history of opportunistic infections. The median survival time was 28 months in KS patients with more than 300 CD4+ lymphocytes (n = 18), but only 14 months in immutiosuppressed (less than 300 CD4+ lymphocytes) individuals with KS (n = 70). The median survival time in the entire group evaluated (n = 89 patients) was 17 months after first diagnosis. In 71 HIV-infected individuals who died at the Berlin Department during the last 8 years, disseminated KS was the major direct or indirect cause of death (49% of cases).

Therapeutic benefit for KS patients was observed after long-term administration of recombinant interferon alpha (rIFN-α; 9–18 million IU s.c. every 2 days) alone or combined with antiretroviral drugs such as zidovudine over several months. Prolongation of survival was found after such treatment modalities in 30%–40% of treated patients. Bleomycin and vincristine and other systemically used cytostatics have also been applied with moderate results.

The etiology of HIV-associated KS is still unknown and coinfection with herpes simplex virus (HSV), cytomegalovirus (CMV), or human papillomavirus (HPV) as well as certain growth-stimulating cytokines (transforming growth factors, TGF; tumor necrosis factor alpha, TNF-α; in-terleukin-6, IL-6; tat; vascular endothelial growth factors, VEGF; oncostatin M) produced by HIV-infected cells may be cofactors. Overall, KS was found to be a tumor with high malignant potential, and the median survival times were short. In spite of the poor prognosis, management and treatment results were improved by use of IFN-α, antiretroviral and cytotoxic drugs, and by the growing experience of the medical community with this HIV-associated tumor.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Acquire Immune Deficiency Syndrome Human Immunodeficiency Virus Patient Acquire Immune Deficiency Syndrome Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrams DI, Volberding PA (1986) Alpha interferon therapy of AIDS-associated Kaposi’s sarcoma. Semin Oncol 13 [3 Suppl 2]:43–47PubMedGoogle Scholar
  2. Archibald CP, Schechter MT, Craib KJ, Le TN, Douglas B, Willoughby B, O’Shaughnessy M (1990) Risk factors for Kaposi’s sarcoma in the Vancouver Lymphadenopathy-AIDS Study. J Acquir Immune Defic Syndr 3 [Suppl 1]:S18–S23PubMedGoogle Scholar
  3. Barrison IG, Foster S, Harris JW, Pinching AJ, Walker JG (1988) Upper gastrointestinal Kaposi’s sarcoma in patients positive for HIV antibody without cutaneous disease. Br Med J Clin Res Ed 296:92–93PubMedCrossRefGoogle Scholar
  4. Bary M, Vittecoq D, Liotier JY, Calamy G (1991) Heterosexual transmission of the aetiological agent of Kaposi’s sarcoma. Lancet 337:234PubMedCrossRefGoogle Scholar
  5. Beral V, Peterman TA, Berkelman RL, Jaffe HW (1990) Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335:123–128PubMedCrossRefGoogle Scholar
  6. Border EC, Ball LA (1981) Interferons: biochemical, cell growth, inhibitory, and immunological effects. Prog Hematol 12:299–239Google Scholar
  7. Border EC, Hogan TF, Voelkel JG (1982) Comparative antiproliferative activity in vitro of natural interferons a and ß for diploid and human cells. Cancer Res 42:4948–4953Google Scholar
  8. Boudreaux AA, Smith LL, Cosby CD, Bason MM, Tappero JW, Berger TG (1993) Intralesional vinblastine for cutaneous Kaposi’s sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol 28:61–65PubMedCrossRefGoogle Scholar
  9. Bratzke B, Stadler R, Eichhorn R, Ehlers G, Orfanos CE (1987) Disseminiertes mukokutanes Kaposi-Sarkom bei AIDS. Klinische und therapeutische Erfahrungen an 13 Patienten. Hautarzt 38:286–294PubMedGoogle Scholar
  10. Bunikowski R, Estermann J, Koch MA (1992) AIDS in der Bundesrepublik Deutschland: die klinische Manifestation von AIDS. Med Klin 87:1–7Google Scholar
  11. Chachoua A, Krigel R, Lafleur F, Ostreicher R, Speer M, Laubenstein L, Wernz J, Rubenstein P, Zang E, Friedman Kien A (1989) Prognostic factors and staging classification of patients with epidemic Kaposi’s sarcoma. J Clin Oncol 7:774–780PubMedGoogle Scholar
  12. Cooper JS (1990) Optimal treatment of epidemic Kaposi’s sarcoma Int J Radiat Oncol Biol Phys 19:807–808PubMedCrossRefGoogle Scholar
  13. Couturier E, Ancelle Park RA, de Vincenzi I, Downs AM, Brunet JB (1990) Kaposi sarcoma as a sexually transmitted disease. Lancet 335:1105PubMedCrossRefGoogle Scholar
  14. de Wit R, Smit WG, Veenhof KH, Bakker PJ, Oldenburger F, Gonzalez DG (1990) Palliative radiation therapy for AIDS-associated Kaposi’s sarcoma by using a single fraction of 800 cGy. Radiother Oncol 19:131–136PubMedCrossRefGoogle Scholar
  15. Delli-Bovi P, Curatola AM, Kern FG, Greco A, Ittmann M, Basilico C (1987) An oncogene isolated by transfection of Kaposi’s sarcoma DNA encodes a growth factor that is a member of the FGF family. Cell 50:729–737PubMedCrossRefGoogle Scholar
  16. Delli-Bovi P, Donti E, Knowles DM Jr, Friedman Kien A, Luciw PA, Dina D, Dalla Favera R, Basilico C (1986) Presence of chromosomal abnormalities and lack of AIDS retrovirus DNA sequences in AIDS-associated Kaposi’s sarcoma. Cancer Res 46:6333–6338PubMedGoogle Scholar
  17. Drew WL, Conant MA, Miner RC et al (1982) Cytomegalovirus and Kaposi’s sarcoma in young homosexual men. Lancet 2:125–127PubMedCrossRefGoogle Scholar
  18. Dupuy J, Price M, Lynch G, Bruce S, Schwartz M (1993) Intralesional interferon-alpha and zidovudine in epidemic Kaposi’s sarcoma. J Am Acad Dermatol 28:966–972PubMedCrossRefGoogle Scholar
  19. Ensoli B, Nakamura S, Salahuddin SZ, Biberfeld P, Larsson L, Beaver B, Wong Staal F, Gallo RC (1989) AIDS-Kaposi’s sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243:223–226PubMedCrossRefGoogle Scholar
  20. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong Staal F (1990) Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients. Nature 345:84–86PubMedCrossRefGoogle Scholar
  21. Ensoli B, Barillari G, Gallo RC (1991) Pathogenesis of AIDS-associated Kaposi’s sarcoma. Hematol Oncol Clin North Am 5:281–295PubMedGoogle Scholar
  22. Epstein JB, Lozada Nur F, McLeod WA, Spinelli J (1989) Oral Kaposi’s sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intralesional vinblastine. Cancer 64:2424–2430PubMedCrossRefGoogle Scholar
  23. Epstein JB, Scully C (1989) Intralesional vinblastine for oral Kaposi sarcoma in HIV infection. Lancet 2:1100–1101PubMedCrossRefGoogle Scholar
  24. Feigal DW, Katz MH, Greenspan D, Westenhouse J, Winkelstein W Jr, Lang W, Samuel M, Buchbinder SP, Hessol NA, Lifson AR et al (1991) The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 5:519–525PubMedCrossRefGoogle Scholar
  25. Ficarra G, Berson AM, Silverman S Jr, Quivey JM, Lozada Nur F, Sooy DD, Migliorati CA (1988) Kaposi’s sarcoma of the oral cavity: a study of 134 patients with a review of the pathogenesis, epidemiology, clinical aspects, and treatment. Oral Surg Oral Med Oral Pathol 66:543–550PubMedCrossRefGoogle Scholar
  26. Fischl MA (1991) Antiretroviral therapy in combination with interferon for AIDS-Google Scholar
  27. related Kaposi’s sarcoma. Am J Med 90:2S–7SGoogle Scholar
  28. Fischl MA, Uttamchandani RB, Resnick L, Agarwal R, Fletcher MA, Patrone Reese J, Dearmas L, Chidekel J, McCann M, Myers M (1991) A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi’s sarcoma. J Acquir Immune Defic Syndr 4:1–10PubMedGoogle Scholar
  29. Friedman Kien AE, Saltzman BR (1990) Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi’s sarcoma. J Am Acad Dermatol 22:1237–1250CrossRefGoogle Scholar
  30. Friedman Kien L, Lauberstein L, Marmor M et al (1981) Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men — New York City and California. MMWR 30:305–308Google Scholar
  31. Gelmann EP, Preble OT, Steis R, Lane HC, Rook AH, Wesley M, Jacob J, Fauci A, Masur H, Longo D (1985) Human lymphoblastoid interferon treatment of Kaposi’s sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters. Am J Med 78:737–741PubMedCrossRefGoogle Scholar
  32. Gelmann EP, Longo D, Lane HC, Fauci AS, Masur H, Wesley M, Preble OT, Jacob J, Steis R (1987) Combination chemotherapy of disseminated Kaposi’s sarcoma in patients with the acquired immune deficiency syndrome. Am J Med 82:456–462PubMedCrossRefGoogle Scholar
  33. Gill PS, Rarick M, Bernstein Singer M, Harb M, Espina BM, Shaw V, Levine A (1990a) Treatment of advanced Kaposi’s sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 13:315–319PubMedCrossRefGoogle Scholar
  34. Gill PS, Rarick MU, Espina B, Loureiro C, Bernstein Singer M, Akil B, Levine AM (1990b) Advanced acquired immune deficiency syndrome-related Kaposi’s sarcoma. Results of pilot studies using combination chemotherapy. Cancer 65: 1074–1078PubMedCrossRefGoogle Scholar
  35. Gill PS, Rarick M, McCutchan JA, Slater L, Parker B, Muchmore E, Bernstein Singer M, Akil B, Espina BM, Krailo M et al (1991) Systemic treatment of AIDS-related Kaposi’s sarcoma: results of a randomized trial. Am J Med 90:427–433PubMedGoogle Scholar
  36. Giraldo G, Beth E, Henle W et al (1978) Antibody patterns to herpesviruses in Kaposi’s sarcoma. II. Seological association of American Kaposi’s sarcoma with cytomegalovirus. Int J Cancer 22:126–131PubMedCrossRefGoogle Scholar
  37. Groopman JE, Gottlieb MS, Goodman J, Mitsuyasu RT, Conant MA, Prince H, Fahey JL, Derezin M, Weinstein WM, Casavante C et al (1984) Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100:671–676PubMedGoogle Scholar
  38. Hartshorn KL, Vogt MW, Chou TC, Blumberg RS, Byington R, Schooley RT, Hirsch MS (1987) Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother 31:168–172Google Scholar
  39. Harwood AR, Osoba D, Hofstader SL et al (1979) Kaposi’s sarcoma in recipients of renal transplants. Am J Med 67:759–765PubMedCrossRefGoogle Scholar
  40. Haverkos HW (1987) Factors associated with the pathogenesis of AIDS J Infect Dis 156:251–257Google Scholar
  41. Huang YQ, Li JJ, Nicolaides A, Zhang WG, Freidman Kien AE (1992a) Fibroblast growth factor 6 gene expression in AIDS-associated Kaposi’s sarcoma. Lancet 339:1110–1111PubMedCrossRefGoogle Scholar
  42. Huang YQ, Li JJ, Rush MG, Poiesz BJ, Nicolaides A, Jacobson M, Zhang WG, Coutavas E, Abbott MA, Friedman Kien AE (1992b) HPV-16-related DNA sequences in Kaposi’s sarcoma. Lancet 339:515–518PubMedCrossRefGoogle Scholar
  43. Janier M, Morel P, Civatte J (1990) The Koebner phenomenon in AIDS-related Kaposi’s sarcoma. J Am Acad Dermatol 22:125–126PubMedCrossRefGoogle Scholar
  44. Kestens L, Melbye M, Biggar RJ, Stevens WJ, Piot P, De Muynck A, Taelman H, De Feyter M, Paluku L, Gigase PL (1985) Endemic African Kaposi’s sarcoma is not associated with immunodeficiency. Int J Cancer 36:49–54PubMedCrossRefGoogle Scholar
  45. Klein MB, Pereira FA, Kantor I (1974) Kaposi’s sarcoma complicating systemic lupus erythematosus treated with immunosuppression. Arch Dermatol 110:602–604PubMedCrossRefGoogle Scholar
  46. Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K, Lee D, Metcalf JA, Bigley JW, Sawyer LA, Zoon KC et al (1989) Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 111:280–287PubMedGoogle Scholar
  47. Krown SE (1991) Interferon and other biological agents for the treatment of Kaposi’s sarcoma. Hematol Oncol Clin North Am 5:311–322PubMedGoogle Scholar
  48. Krown SE, Real FX, Vadhan Raj S, Cunningham Rundles S, Krim M, Wong G, Oettgen HF (1986) Kaposi’s sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer 57 [Suppl 8]: 1662–1665PubMedCrossRefGoogle Scholar
  49. Krown SE, Metroka C, Wernz JC (1989) Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 7:1201–1207PubMedGoogle Scholar
  50. Krown SE, Pareoles J, Bundow D, Polsky B, Gold JW, Flomenberg N (1992) Interferon alpha, Zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi’s sarcoma associated with AIDS. J Clin Oncol: 1344–1351Google Scholar
  51. Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, Deyton L, Metcalf JA, Baseler M, Salzman N et al (1988) Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi’s sarcoma. Lancet 2:1218–1222PubMedCrossRefGoogle Scholar
  52. Lemlich G, Schwam L, Lebwohl M (1987) Kaposi’s sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases. J Am Acad Dermatol 16:319–325PubMedCrossRefGoogle Scholar
  53. Lilenbaum RC, Ratner E (1994) Systemic treatment of Kaposi’s sarcoma: current status and future directions. AIDS 8:141–151PubMedCrossRefGoogle Scholar
  54. Mayer-da Silva A, Stadler R, Imcke E, Bratzke B, Orfanos CE (1987) Disseminated Kaposi’s sarcoma in AIDS: histogenesis-related populations and influence of long-term treatment with rIFN-αA. J Invest Dermatol 89:618–624CrossRefGoogle Scholar
  55. McKenzie R, Travis WD, Dolan SA, Pittaluga S, Feuerstein IM, Shelhamer J, Yarchoan R, Masur H (1991) The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases. Medicine (Baltimore) 70:326–343CrossRefGoogle Scholar
  56. Miles SA, Rezai AR, Salazar Gonzalez JF, Vander Meyden M, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T et al (1990) AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 87:4068–4072PubMedCrossRefGoogle Scholar
  57. Nair BC, DeVico AL, Nakamura S, Copeland TD, Chen Y, Patel A, O’Neil T, Oroszlan S, Gallo RC, Sarngadharan MG (1992) Identification of a major growth factor for AIDS-Kaposi’s sarcoma cells as oncostatin M. Science 255:1430–1432PubMedCrossRefGoogle Scholar
  58. Nakamura S, Sakurada S, Salahuddin SZ, Osada Y, Tanaka NG, Sakamoto N, Sekiguchi M, Gallo RC (1992) Inhibition of development of Kaposi’s sarcoma-related lesions by a bacterial cell wall complex. Science 255:1437–1440PubMedCrossRefGoogle Scholar
  59. Orfanos CE (1983) Acquired immune deficiency syndrome (AIDS) und disseminiertes Kaposi-Sarkom. Eine neue Infektionskrankheit? Hautarzt 34:319–321PubMedGoogle Scholar
  60. Orfanos CE, Bratzke B, Lehmann FM (1988) Das HIV-1-assoziierte mukokutane Kaposi-Sarkom. AIFO 3:561–569Google Scholar
  61. Payne SF, Lemp GF, Rutherford GW (1990) Survival following diagnosis of Kaposi’s sarcoma for AIDS patients in San Francisco. J Acquir Immune Defic Syndr 3 [Suppl 1]:S14–S17PubMedGoogle Scholar
  62. Peterman TA, Jaffe HW, Beral V (1993) Epidemiologic clues to the etiology of Kaposi’s sarcoma. AIDS 7:605–611PubMedCrossRefGoogle Scholar
  63. Peters BS, Beck EJ, Coleman DG, Wadsworth MJ, McGuinness O, Harris JR, Pinching AJ (1991) Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. BMJ 302:203–207PubMedCrossRefGoogle Scholar
  64. Plettenberg A, Engelmann L, Meigel W (1990a) Pathogenese des HIV-assoziierten Kaposi-Sarkoms — das Koebner-Phänomen als möglicher Auslösemechanismus. Z Hautkr 65:684–686, 689Google Scholar
  65. Plettenberg A, Kern P, Dietrich M, Meigel W (1990b) Rekombinantes Interferon alpha 2A n der Behandlung des HIV-assoziierten Kaposi-Sarkoms. Langzeitergebnisse. Med Klin 85:647–652Google Scholar
  66. Plettenberg A, Janik I, Kolb H, Meigel W (1991) Lokaltherapeutische Massnahmen beim HIV-assoziierten Kaposi-Sarkom mit besonderer Berucksichtigung der Rontgenweichstrahltherapie. Strahlenther Onkol 167:208–213PubMedGoogle Scholar
  67. Real FX, Krown SE (1985) Spontaneous regression of Kaposi’s sarcoma in patients with AIDS. N Engl J Med 313:1659PubMedGoogle Scholar
  68. Peal FX, Oettgen HF, Krown SE (1986) Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4:544–551Google Scholar
  69. Rendon MI, Roberts LJ, Tharp MD (1988) Linear cutaneous lesions of Kaposi’s sarcoma: a clinical clue to the diagnosis of acquired immunodeficiency syndrome. Arch Dermatol 124:327–329PubMedCrossRefGoogle Scholar
  70. Rios A, Mansell PW, Newell GR, Reuben JM, Hersh EM, Gutterman JU (1985) Treatment of acquired immunodeficiency syndrome-related Kaposi’s sarcoma with lymphoblastoid interferon. J Clin Oncol 3:506–512PubMedGoogle Scholar
  71. Rozenbaum W, Gharakhanian S, Navarette MS, De Sahb R, Cardon B, Rouzioux C (1990) Long-term follow-up of 120 patients with AIDS-related Kaposi’s sarcoma treated with interferon alpha-2a. J Invest Dermatol 95 [Suppl 6]:161S–165SPubMedCrossRefGoogle Scholar
  72. Ruprecht RM, Chou TC, Chipty F, Sosa MG, Mullaney S, O’Brien L, Rosas D (1990) Interferon-alpha and 3’-azido-3’-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure. J Acquir Immune Defic Syndr 3:591–600PubMedGoogle Scholar
  73. Ruszczak Z, Mayer-da-Silva A, Orfanos CE (1987) Kaposi’s sarcoma in AIDS. Multicentric angioneoplasia in early skin lesions. Am J Dermatopathol 9:388–398PubMedCrossRefGoogle Scholar
  74. Ruszczak Z, Stadler R, Orfanos CE (1991) Immunphenotyping of HIV-associated Kaposi’s sarcoma cells in vivo and in vitro: influence of rIFN-alpha and rIFN-gamma. J Invest Dermatol 96(6): 1005Google Scholar
  75. Rutherford GW, Schwarcz SK, Lemp GF, Barnhart JL, Rauch KJ, Warner WL, Piland TH, Werdegar D (1989) The epidemiology of AIDS-related Kaposi’s sarcoma in San Francisco. J Infect Dis 159:569–572PubMedCrossRefGoogle Scholar
  76. Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, Groopman JE (1991a) GM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment fo AIDS-associated Kaposi’s sarcoma. Am J Clin Oncol 14 [Suppl 1]:S40–S44PubMedCrossRefGoogle Scholar
  77. Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, Groopman JE (1991b) Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi’s sarcoma. J Clin Oncol 9:802–808PubMedGoogle Scholar
  78. Schaart FM, Bratzke B, Ruszczak Z, Stadler R, Ehlers G, Orfanos CE (1991) Long-term therapy of HIV-associated Kaposi’s sarcoma with recombinant interferon alpha-2a. Br J Dermatol 124:62–68PubMedCrossRefGoogle Scholar
  79. Schöfer H, Ochsendorf FR, Hochscheid I, Milbradt R (1991) Kaposi-Sarkome im Gesicht. Palliative Behandlung mit Kryochirurgie, intraläsionaler Chemotherapie, Röntgenweichstrahltherapie und Camouflage. Hautarzt 42:492–498PubMedGoogle Scholar
  80. Schröder K, Garbe C, Waibel M, Reupke H, Detmar M, Dallenbach F, Orfanos CE (1992) Granulozyten-Koloniestimulierender Faktor (G-CSF) in der Behandlung von Patienten mit HIV-assoziiertem mukokutanem Kaposi-Sarkom. Erfolgreicher Einsatz bei virus- bzw. medikamenteninduzierter Leukopenie. Hautarzt 43:700–706PubMedGoogle Scholar
  81. Sidky YA, Borden EC (1987) Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47:5155–5161PubMedGoogle Scholar
  82. Silverman S Jr, Migliorati CA, Lozada Nur F, Greenspan D, Conant MA (1986) Oral findings in people with or at high risk for AIDS: a study of 375 homosexual males. J Am Dent Assoc 112:187–192PubMedGoogle Scholar
  83. Spornraft P, Froschl M, Ring J, Meurer M, Goebel FD, Ziegler Heitbrock HW, Riethmuller G, Braun Falco O (1988) T4/T8 ratio and absolute T4 cell numbers in different clinical stages of Kaposi’s sarcoma in AIDS. Br J Dermatol 119:1–9PubMedCrossRefGoogle Scholar
  84. Stadler R, Bratzke B, Mayer-da-Silva A, Carbe C, Orfanos CE (1989) Interferons in dermatology. J Am Acad Dermatol 20:650–656PubMedCrossRefGoogle Scholar
  85. Stadler R, Bratzke B, Schaart F, Orfanos CE (1990) Long-term combined rIFN-alpha-2a and zidovudine therapy for HIV-associated Kaposi’s sarcoma: clinical consequences and side effects. J Invest Dermatol 95 [Suppl 6]:170S–175SPubMedCrossRefGoogle Scholar
  86. Sulis E, Floris C, Sulis ML, Zurrida S, Piro S, Pintus A, Contu L (1989) Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi’s sarcoma. Eur J Cancer Clin Oncol 25:759–761PubMedCrossRefGoogle Scholar
  87. Tappero JW, Berger TG, Kaplan LD, Volberding PA, Kahn JO (1991) Cryotherapy for cutaneous Kaposi’s sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr 4:839–846PubMedGoogle Scholar
  88. Tappero JW, Grekin RC, Zanelli GA, Berger TG (1992) Pulsed-dye laser therapy for cutaneous Kaposi’s sarcoma associated with acquired immunodeficiency syndrome. J Am Acad Dermatol 27:526–530PubMedCrossRefGoogle Scholar
  89. Tebbe B, Mayer da Silva A, Garbe C, von Keyserlingk HJ, Orfanos CE (1991) Genetically determined coincidence of Kaposi sarcoma and psoriasis in an HIV-negative patient after prednisolone treatment. Spontaneous regression 8 months after discontinuing therapy. Int J Dermatol 30:114–120PubMedCrossRefGoogle Scholar
  90. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G (1988) The HIV tat gene induces dermal lesions resembling Kaposi’s sarcoma in transgenic mice. Nature 335:606–611PubMedCrossRefGoogle Scholar
  91. Volberding P, Valero R, Rothman J, Gee G (1984) Alpha interferon therapy of Kaposi’s sarcoma in AIDS. Ann NY Acad Sci 437:439–446PubMedCrossRefGoogle Scholar
  92. Vossmann D, Thies W, Bauer R, Orfanos CE (1983) Disseminiertes Kaposi-Sarkom der Haut bei einem jungen Homosexuellen mit Drogenabus. Hautarzt 34:339–345PubMedGoogle Scholar
  93. Wahman A, Melnick SL, Rhame FS, Potter JD (1991) The epidemiology of classic, African, and immunosuppressed Kaposi’s sarcoma. Epidemiol Rev 13:178–199PubMedGoogle Scholar
  94. Weindel K, Marme D, Weich HA (1992) AIDS-associated Kaposi’s sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun 183:1167–1174PubMedCrossRefGoogle Scholar
  95. Xerri L, Hassoun J, Planche J, Guigou V, Grob JJ, Parc P, Birnbaum D, deLapeyriere O (1991) Fibroblast growth factor gene expression in AIDS-Kaposi’s sarcoma detected by in situ hybridization. Am J Pathol 138:9–15PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1995

Authors and Affiliations

  • C. E. Orfanos
    • 1
  • R. Husak
    • 1
  • U. Wölfer
    • 1
  • C. Garbe
    • 1
  1. 1.Department of DermatologyUniversity Medical Center Steglitz, The Free University of BerlinBerlinGermany

Personalised recommendations